Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 30920987.
- Also identified by DOI 10.14309/ajg.0000000000000186.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite encouraging data gathered in inflammatory bowel diseases (IBD) patients, Vedolizumabs' (VDZ) safety profile in pregnancy is not established. Data of 330 consecutive pregnancies with IBD was prospectively collected. Women with IBD were treated with: VDZ (n = 24), anti-tumor necrosis factors (n = 82) or conventional therapy (n = 224). Gravidity and parity were similar among the 3 groups. The VDZ group was comprised mostly of Crohn's disease patients who were all not naïve to biological treatment. They had significantly higher conception rates during active disease (P < 0.05), with fewer flares during pregnancy. Although further study is needed, VDZ appears of low risk during pregnancy.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Inflammatory Bowel Diseases
- Patient Safety
- Pregnancy Outcome
- Tumor Necrosis Factor-alpha